17 results on '"Stephen, McAdoo"'
Search Results
2. Lack of seroresponse to SARS-CoV-2 booster vaccines given early post-transplant in patients primed pre-transplantation
- Author
-
Sarah Gleeson, Paul Martin, Tina Thomson, Katrina J. Spensley, Dawn Goodall, Rachna Bedi, Amarpreet Kaur Thind, Charlotte Seneschall, Jaslyn Gan, Stephen McAdoo, Liz Lightstone, Peter Kelleher, Maria Prendecki, and Michelle Willicombe more...
- Subjects
SARS-CoV-2 ,COVID- 19 ,immunosuppressed ,kidney transplant ,vaccine ,infection ,Immunologic diseases. Allergy ,RC581-607 - Abstract
SARS-CoV-2 vaccines are recommended pre-transplantation, however, waning immunity and evolving variants mandate booster doses. Currently there no data to inform the optimal timing of booster doses post-transplant, in patients primed pre-transplant. We investigated serial serological samples in 204 transplant recipients who received 2 or 3 SARS-CoV-2 vaccines pre-transplant. Spike protein antibody concentrations, [anti-S], were measured on the day of transplantation and following booster doses post-transplant. In infection-naïve patients, post-booster [anti-S] did not change when V3 (1st booster) was given at 116(78-150) days post-transplant, falling from 122(32-574) to 111(34-682) BAU/ml, p=0.78. Similarly, in infection-experienced patients, [anti-S] on Day-0 and post-V3 were 1090(133-3667) and 2207(650-5618) BAU/ml respectively, p=0.26. In patients remaining infection-naïve, [anti-S] increased post-V4 (as 2nd booster) when given at 226(208-295) days post-transplant, rising from 97(34-1074) to 5134(229-5680) BAU/ml, p=0.0016. Whilst in patients who had 3 vaccines pre-transplant, who received V4 (as 1st booster) at 82(49-101) days post-transplant, [anti-S] did not change, falling from 981(396-2666) to 871(242-2092) BAU/ml, p=0.62. Overall, infection pre-transplant and [anti-S] at the time of transplantation predicted post-transplant infection risk. As [Anti-S] fail to respond to SARS-CoV-2 booster vaccines given early post-transplant, passive immunity may be beneficial to protect patients during this period. more...
- Published
- 2023
- Full Text
- View/download PDF
Catalog
3. Severe COVID‐19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis
- Author
-
Golzar Mobayen, Amrita Dhutia, Candice Clarke, Maria Prendecki, Stephen McAdoo, Renos Keniyopoullos, Talat Malik, Michael Laffan, Michelle Willicombe, and Thomas McKinnon
- Subjects
ADAMTS‐13 ,COVID‐19 ,endothelium ,glycosylation ,von Willebrand factor ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract Background A major clinical feature of severe coronavirus diease 2019 (COVID‐19) is microvascular thrombosis linked to endothelial cell activation. Consistent with this, a number of studies have shown that patients with severe COVID‐19 have highly elevated plasma levels of von Willebrand Factor (VWF) that may contribute to the prothrombotic phenotype. In the current study, we investigated the extent of endothelial activation in patients receiving hemodialysis who had either mild or severe COVID‐19. Methods Plasma VWF, ADAMTS‐13, angiopoietin‐2 (Ang2), and syndecan‐1 levels were determined by ELISA. The sialic acid content of VWF was investigated using a modified ELISA to measure elderberry bark lectin, specific for sialic acid residues, binding to VWF. Results Patients receiving hemodialysis with severe COVID‐19 had significantly higher plasma levels of VWF and lower ADAMTS‐13. VWF levels peaked and were sustained during the first 10 days after positive confirmation of infection. While Ang2 trended toward being higher in severely ill patients, this did not reach significance; however, severely ill patients had significantly higher soluble syndecan‐1 levels, with high levels related to risk of death. Finally, higher VWF levels in severely ill patients were correlated with lower VWF sialic acid content. Conclusions Severe COVID‐19 in patients undergoing hemodialysis is associated with both acute and sustained activation of the endothelium, leading to alteration of the VWF/ADAMTS‐13 axis. Lower VWF sialic acid content represents altered VWF processing and further confirms the disturbance caused to the endothelium in COVID‐19. more...
- Published
- 2021
- Full Text
- View/download PDF
4. Secondary glomerular disease
- Author
-
Mukunthan Srikantharajah and Stephen McAdoo
- Subjects
General Medicine - Published
- 2023
- Full Text
- View/download PDF
5. Risk Stratification to Predict Renal Survival in Anti–Glomerular Basement Membrane Disease
- Author
-
Lauren Floyd, Sebastian Bate, Abdul Hadi Kafagi, Nina Brown, Jennifer Scott, Mukunthan Srikantharajah, Marek Myslivecek, Graeme Reid, Faten Aqeel, Doubravka Frausova, Marek Kollar, Phuong Le Kieu, Bilal Khurshid, Charles D. Pusey, Ajay Dhaygude, Vladimir Tesar, Stephen McAdoo, Mark A. Little, Duvuru Geetha, and Silke R. Brix more...
- Subjects
Nephrology ,General Medicine - Published
- 2022
- Full Text
- View/download PDF
6. ANCA‐associated Vasculitis
- Author
-
Maria Prendecki and Stephen McAdoo
- Published
- 2022
- Full Text
- View/download PDF
7. ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap
- Author
-
Hans-Joachim Anders, Brad Rovin, David Jayne, Paul Brunetta, Rosanna Coppo, Anne Davidson, Satish Kumar Devarapu, Dick de Zeeuw, Jeremy Duffield, Dirk Eulberg, Alberto Fierro, Jürgen Floege, Steffen Frese, Loïc Guillevin, Stephen Holdsworth, Jeremy Hughes, Ralph Kettritz, Malte Kluger, Christian Krebs, Larissa Lapteva, Adeera Levin, Jinhua Li, Liz Lightstone, Matthias Mack, Ladan Mansouri, Stephen McAdoo, Eoin McKinney, Ulf Panzer, Samir Parikh, Charles Pusey, Chaim Putterman, Ton Rabelink, Andreas Radbruch, Andrew Rees, Mary Reilly, Marlies Reinders, Giuseppe Remuzzi, Piero Ruggenenti, Steven Sacks, Thomas J Schall, Catherine Meyer-Schwesinger, Kumar Sharma, Yusuke Suzuki, Nicola M. Tomas, and Ming-Hui Zhao more...
- Subjects
autoimmunity ,inflammation ,lupus ,rejection ,stem cells ,vasculitis ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases. more...
- Published
- 2016
- Full Text
- View/download PDF
8. ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives
- Author
-
Keziah Austin, Shalini Janagan, Matthew Wells, Helena Crawshaw, Stephen McAdoo, and Joanna C Robson
- Subjects
Immunology ,Immunology and Allergy - Abstract
The ANCA associated vasculitides (AAVs) affect a range of internal organs including ear nose and throat, respiratory tract, kidneys, skin and nervous system. They include granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) and microscopic polyangiitis (MPA). The AAVs are treated with high dose glucocorticoids, immunosuppressants, and targeted biological medications. Since the 1990s classification criteria for the AAVs have been based on clinical features, laboratory tests and basic imaging; an initiative to update the classification criteria incorporating newer tests, for example, anti-neutrophil cytoplasmic antibodies (ANCA) and novel imaging techniques will be published this year. There is also evidence for classification of patients based on ANCA subtype; those with anti-proteinase 3 antibodies (PR3) or anti-myeloperoxidase antibodies (MPO) have differences in response to treatment and clinical outcomes. An update is described within this review. The pathogenesis of AAV involves necrotizing inflammation of small to medium blood vessels involving multiple immunological pathways. We present an update on emerging evidence related to auto-antibodies, complement and lymphocyte pathways. This review describes emerging treatment regimens, including evidence for plasma exchange in severe disease and the inhibitor of the complement C5a receptor (C5aR) inhibitor, Avacopan. Lastly, patient reported outcomes are key secondary outcomes in randomised controlled trials and increasingly clinical practice, we report development in disease specific and glucocorticoid-specific PROs. more...
- Published
- 2022
- Full Text
- View/download PDF
9. The Kidney in Auto-Immune and Auto-Inflammatory Processes: Definitions, Mechanisms, and Biomarkers
- Author
-
Gian Marco Ghiggeri, Stephen McAdoo, Laura Piera Obici, Augusto Vaglio, and Marco Gattorno
- Published
- 2023
- Full Text
- View/download PDF
10. ANCA associated vasculitis subtypes: response [response to letter]
- Author
-
Keziah Austin, Shalini Janagan, Matthew Wells, Helena Crawshaw, Stephen McAdoo, and Joanna C Robson
- Subjects
Immunology ,Immunology and Allergy ,Journal of Inflammation Research - Abstract
Keziah Austin,1 Shalini Janagan,2 Matthew Wells,3 Helena Crawshaw,4 Stephen McAdoo,5 Joanna C Robson2,6 1Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK; 2Department of Rheumatology, Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK; 3Department of Rheumatology, Great Western Hospital, Swindon, UK; 4Department of Rheumatology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK; 5Department of Medicine, Imperial College London, London, UK; 6Faculty of Health and Applied Sciences, University of the West of England, Bristol, UKCorrespondence: Keziah Austin, Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK, Email Keziah.austin1@nhs.net more...
- Published
- 2022
11. Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients
- Author
-
Edward J Carr, Mary Wu, Ruth Harvey, Roseanne E Billany, Emma C Wall, Gavin Kelly, Michael Howell, George Kassiotis, Charles Swanton, Sonia Gandhi, David LV Bauer, Matthew PM Graham-Brown, Rachel B Jones, Rona M Smith, Stephen McAdoo, Michelle Willicombe, and Rupert Beale more...
- Subjects
General Medicine - Published
- 2022
- Full Text
- View/download PDF
12. Risk Stratification to Predict Renal Survival in Anti-GBM Disease
- Author
-
Lauren, Floyd, Sebastian, Bate, Abdul, Kafagi, Nina, Brown, Jennifer, Scott, Mukunthan, Srikantharajah, Marek, Mysilvecek, Graeme, Reid, Faten, Aqeel, Doubravka, Frausova, Marek, Kollar, Phuong Le, Kieu, Bilal, Khurshid, Ajay, Dhaygude, Vladimir, Tesar, Stephen, McAdoo, Mark, Little, Duvuru, Geetha, and Silke, Brix more...
- Abstract
Anti-glomerular basement membrane (GBM) disease is a rare, aggressive vasculitis with no validated prediction tools to assist its management. We investigated a retrospective multicenter international cohort with the aim to transfer the Renal Risk Score (RRS) and to identify patients that benefit from rescue immunosuppressive therapy. Of a total 191 patients, 174 patients were included in the final analysis (57% female, median age 59 years). Using Cox and Kaplan-Meier methods, the RRS was found to be a strong and effective predictor for end stage kidney disease (ESKD) with a model concordance of C=0.760. The 36-month renal survival was 100%, 62.4%, and 20.7% in the low-, moderate-, and high-risk groups, respectively (P0.001). The need for renal replacement therapy (RRT) at diagnosis and the percentage of normal glomeruli in the biopsy were independent predictors of ESKD (P0.001, P0.001). Considering the 129 patients initially requiring RRT, the best predictor for renal recovery was the percentage of normal glomeruli (C=0.622; P0.001), a split either side of 10% providing good stratification. A model with the predictors RRT and normal glomeruli (N) achieved superior discrimination (C=0.840, P0.001). Dividing patients into four risk groups led to a 36-month renal survival of 96.4% (no RRT, N≥10%), 74.0% (no RRT, N10%), 42.3% (RRT, N≥10%) and 14.1% (RRT, N10%), respectively. In summary, we demonstrate that the RRS concept is transferrable to anti-GBM disease. Stratifying patients according to the need for RRT at diagnosis and renal histology improves prediction, highlighting the importance of normal glomeruli. Here, we propose a stratification to assist in the management of anti-GBM disease. more...
- Published
- 2022
13. Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease
- Author
-
Fredrik Uhlin, Wladimir Szpirt, Andreas Kronbichler, Annette Bruchfeld, Inga Soveri, Lionel Rostaing, Eric Daugas, Arnaud Lionet, Nassim Kamar, Cédric Rafat, Marek Mysliveček, Vladimír Tesař, Anders Fernström, Christian Kjellman, Charlotte Elfving, Stephen McAdoo, Johan Mölne, Ingeborg Bajema, Elisabeth Sonesson, and Mårten Segelmark more...
- Subjects
Adult ,Male ,Anti-Glomerular Basement Membrane Disease ,Goodpasture syndrome ,Pilot Projects ,clinical trial ,General Medicine ,Middle Aged ,Kidney ,Basement Membrane ,endopeptidases ,Young Adult ,Nephrology ,Clinical Research ,Humans ,Female ,Kidney Diseases ,anti-GBM disease ,glomerulonephritis ,Aged ,Autoantibodies - Abstract
BACKGROUND: The prognosis for kidney survival is poor in patients presenting with circulating anti–glomerular basement membrane (GBM) antibodies and severe kidney injury. It is unknown if treatment with an endopeptidase that cleaves circulating and kidney bound IgG can alter the prognosis. METHODS: An investigator-driven phase 2a one-arm study (EudraCT 2016–004082–39) was performed in 17 hospitals in five European countries. A single dose of 0.25 mg/kg of imlifidase was given to 15 adults with circulating anti-GBM antibodies and an eGFR more...
- Published
- 2022
- Full Text
- View/download PDF
14. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients
- Author
-
Edward J Carr, Mary Wu, Ruth Harvey, Emma C Wall, Gavin Kelly, Saira Hussain, Michael Howell, George Kassiotis, Charles Swanton, Sonia Gandhi, David LV Bauer, Roseanne E Billany, Matthew PM Graham-Brown, Joseph Beckett, Katherine Bull, Sushma Shankar, Scott Henderson, Reza Motallebzadeh, Alan D Salama, Lorraine Harper, Patrick B Mark, Stephen McAdoo, Michelle Willicombe, Rupert Beale, Sherna F Adenwalla, Paul Bird, Christopher Holmes, Katherine L Hull, Daniel S March, Haresh Selvaskandan, Jorge J Silva, Julian W Tang, Joanna Hester, Fadi Issa, Martin Barnardo, Peter J Friend, Andrew Davenport, Catriona Goodlad, Vignesh Gopalan, Theerasak Tangwonglert, Hans J Stauss, Alex G Richter, Adam F Cunningham, Marisol Perez-Toledo, Gemma D Banham, Nadya Wall, Candice L Clarke, Maria Prendecki, Bobbi Clayton, Sina Namjou, Vanessa Silva, Meghan Poulten, Philip Bawumia, Murad Miah, Samuel Sade, Mauro Miranda, Tom Taylor, Ilenia D'Angelo, Mercedes Cabrera Jarana, Mahbubur Rahman, Janet Abreu, Sandeep Sandhar, Neil Bailey, Simon Caidan, Marie Caulfield, Lorin Adams, Caitlin Kavanagh, Scott Warchal, Chelsea Sawyer, Mike Gavrielides, Jag Kandasamy, Karen Ambrose, Amy Strange, Titilayo Abiola, Nicola O'Reilly, Philip Hobson, Ana Agau-Doce, Emma Russell, Andrew Riddell, Svend Kjaer, Annabel Borg, Chloë Roustan, consortium, Haemodialysis COVID-19, and Pipeline, Crick COVID Immunity more...
- Subjects
Reino unido ,2019-20 coronavirus outbreak ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,biology ,business.industry ,SARS-CoV-2 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Vaccination ,COVID-19 ,General Medicine ,Antibodies, Viral ,Virology ,Antibodies, Neutralizing ,United Kingdom ,Renal Dialysis ,Correspondence ,biology.protein ,Medicine ,Humans ,Antibody ,business - Abstract
No abstract available.
- Published
- 2021
15. Identification of Patient Characteristics Associated With SARS-CoV-2 Infection and Outcome in Kidney Transplant Patients Using Serological Screening
- Author
-
Michelle, Willicombe, Sarah, Gleeson, Candice, Clarke, Frank, Dor, Maria, Prendecki, Liz, Lightstone, Gaetano, Lucisano, Stephen, McAdoo, and David, Thomas
- Subjects
Adult ,Male ,SARS-CoV-2 ,Immunology ,COVID-19 ,Renal transplantation ,Middle Aged ,Antibodies, Viral ,Kidney Transplantation ,COVID-19 Serological Testing ,SARS-CoV2 ,Humans ,Acute rejection ,Female ,Vaccine ,Immunosuppressive Agents ,Clinical Practice: Second Opinion ,Aged - Abstract
From population studies, solid organ transplant recipients are at increased risk of mortality from RT-PCR confirmed COVID-19 infection. The risk factors associated with infection acquisition and mortality in transplant recipients using serological data have not been reported.From 1725 maintenance transplant recipients, 855 consecutive patients were screened for SARS-CoV-2 antibodies. Serological screening utilized assays to detect both the N protein and receptor binding domain antibodies. Thirty-three of 855 (3.9%) of the screened patients had prior infection confirmed with RT-PCR. Twenty-one additional patients from our 1725 maintenance cohort with RT-PCR confirmed infection were included in our analysis.Eighty-nine of 855 (10.4%) patients tested positive for SARS-CoV-2 antibodies. Fifty-nine of 89 (66.3%) cases were patients newly identified as exposed, while 30/89 (33.7%) seropositive patients had previous infection confirmed by RT-PCR. A diagnosis of SARS-CoV-2 (RT-PCR or Ab+) was associated with being from a noncaucasoid background, P = 0.015; having a diagnosis of diabetes, P = 0.028 and a history of allograft rejection, P 0.01. Compared with the RT-PCR+ cohort, patients with serological-proven infection alone were more likely to be receiving tacrolimus monotherapy, P 0.01, and less likely to have a diagnosis of diabetes, P = 0.012. Seventeen of 113 (15.0%) of all patients with infection (RT-PCR and Ab+) died. Risk factors associated with survival were older age, odds ratio (OR): 1.07 (1.00-1.13), P = 0.041; receiving prednisolone, OR: 5.98 (1.65-21.60), P 0.01 and the absence of diabetes, OR: 0.27 (0.07-0.99), P = 0.047.This study identifies risk factors and outcome for COVID-19 infection incorporating data on serologically defined infection and highlights the important contribution of immunosuppression regimen on outcomes. more...
- Published
- 2020
16. Comment on: A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis: reply
- Author
-
Alan Salama, Ruth Pepper, Stephen Mcadoo, and Charles Pusey
- Subjects
Cytoplasm ,Science & Technology ,Rheumatology ,1107 Immunology ,Humans ,Pharmacology (medical) ,1103 Clinical Sciences ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ,Life Sciences & Biomedicine ,Cyclophosphamide ,Glucocorticoids ,Arthritis & Rheumatology ,1117 Public Health and Health Services - Published
- 2019
17. Clinical characteristics and outcomes of HIV-associated immune complex kidney disease
- Author
-
John W, Booth, Lisa, Hamzah, Sophie, Jose, Catherine, Horsfield, Patrick, O'Donnell, Stephen, McAdoo, Emil A, Kumar, Tabitha, Turner-Stokes, Nadia, Khatib, Partha, Das, Claire, Naftalin, Nicola, Mackie, Ed, Kingdon, Debbie, Williams, Bruce M, Hendry, Caroline, Sabin, Rachael, Jones, Jeremy, Levy, Rachel, Hilton, John, Connolly, Frank A, Post, and K, Wakeman more...
- Subjects
Adult ,Male ,030232 urology & nephrology ,Renal function ,Disease ,urologic and male genital diseases ,Kidney ,Nephropathy ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,medicine ,Humans ,030212 general & internal medicine ,AIDS-Associated Nephropathy ,Transplantation ,Proteinuria ,business.industry ,Glomerulonephritis, IGA ,Middle Aged ,medicine.disease ,CD4 Lymphocyte Count ,Treatment Outcome ,Renal pathology ,Nephrology ,Immunology ,Disease Progression ,Kidney Failure, Chronic ,RNA, Viral ,Female ,medicine.symptom ,business ,Kidney disease ,Glomerular Filtration Rate - Abstract
BACKGROUND The pathogenesis and natural history of HIV-associated immune complex kidney disease (HIVICK) is not well understood. Key questions remain unanswered, including the role of HIV infection and replication in disease development and the efficacy of antiretroviral therapy (ART) in the prevention and treatment of disease. METHODS In this multicentre study, we describe the renal pathology of HIVICK and compare the clinical characteristics of patients with HIVICK with those with IgA nephropathy and HIV-associated nephropathy (HIVAN). Poisson regression models were used to identify risk factors for each of these pathologies. RESULTS Between 1998 and 2012, 65 patients were diagnosed with HIVICK, 27 with IgA nephropathy and 70 with HIVAN. Black ethnicity and HIV RNA were associated with HIVICK, receipt of ART with IgA nephropathy and black ethnicity and CD4 cell count with HIVAN. HIVICK was associated with lower rates of progression to end-stage kidney disease compared with HIVAN and IgA nephropathy (P < 0.0001). Patients with HIVICK who initiated ART and achieved suppression of HIV RNA experienced improvements in estimated glomerular filtration rate and proteinuria. CONCLUSIONS These findings suggest a pathogenic role for HIV replication in the development of HIVICK and that ART may improve kidney function in patients who have detectable HIV RNA at the time of HIVICK diagnosis. Our data also suggest that IgA nephropathy should be viewed as a separate entity and not included in the HIVICK spectrum. more...
- Published
- 2015
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.